NAD RFQ1 - Humira by Cordavis - TIB - TNFI.xlsx
XLSX spreadsheet 47 KB Posted
- Solicitation number
- HT9402-24-Q-9302
- Issued by
-
Defense Health Agency
About this file
This document is a Request for Quotation (RFQ) issued by the Defense Health Agency (DHA) for the Department of Defense (DoD) Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program. The RFQ is seeking quotes from industry for pharmaceutical agents within the Targeted Immunomodulatory Biologics drug class, Tumor Necrosis Factor Inhibitors subclass, to be considered for placement on the DoD Uniform Formulary at the August 2024 Pharmacy and Therapeutics (P&T) Committee meeting. Quotes are due by May 9, 2024, and the DHA may award Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements based on the P&T Committee's formulary decisions. The document includes pricing templates, formulary scenarios, and other details related to the required submissions.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| NAD RFQ1 - Simlandi - TIB - TNFI.xlsx | XLSX spreadsheet | |
| RFQ HT9402-24-Q-9302 NAD.pdf | ||
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| Price Appendix FAQ NAD.pdf | ||
| NAD RFQ1 - Rezdiffra - GAST-2 AGENTS - NA.xlsx | XLSX spreadsheet |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the August 2024 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 |
| Formulary Notes | |||
| Class Note(s): Step may apply. |
Step Therapy Addendum: Grandfathering will apply. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 20144TGTNNFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 20144TGTNNFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 20144TGTNNFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 20144TGTNNFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 20144TGTNNFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 20144TGTNNFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 20144TGTNNFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 20144TGTNNFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 20144TGTNNFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 20144TGTNNFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (non-FAMP Discount)
| UF ADP Appendix for the August 2024 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 |
| Formulary Notes | |||
| Class Note(s): Step may apply. |
Step Therapy Addendum: Grandfathering will apply. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (WAC Discount)
| UF ADP Appendix for the August 2024 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 |
| Formulary Notes | |||
| Class Note(s): Step may apply. |
Step Therapy Addendum: Grandfathering will apply. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | May 9, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 20144TGTNT3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
File details come from the government source that posted it. Updated .